About
Rasburicase is a recombinant urate oxidase enzyme specifically designed for the management and prevention of acute hyperuricemia, a severe complication often associated with tumor lysis syndrome (TLS). TLS occurs when a large number of cancer cells are rapidly destroyed, releasing their intracellular contents, including purines, which are then metabolized into uric acid. Rasburicase catalyzes the enzymatic oxidation of uric acid into allantoin, a highly soluble and readily excretable compound, thereby rapidly lowering plasma uric acid levels. This swift reduction in uric acid is crucial for preventing acute kidney injury, renal failure, and other systemic complications that can arise from hyperuricemia in patients undergoing chemotherapy for hematologic malignancies or those at high risk of TLS. Its targeted action provides a critical intervention to mitigate these life-threatening metabolic disturbances.
Uses
- Prevention of acute hyperuricemia in TLS
- Treatment of existing hyperuricemia in TLS
- Management of high uric acid levels in cancer patients
- Adjunct therapy during chemotherapy for high-risk TLS
Directions For Use
Administer intravenously as a single daily infusion over 30 minutes.
Benefits
- Rapidly lowers uric acid levels
- Prevents acute kidney injury in TLS
- Reduces need for dialysis in TLS
- Effective in high-risk cancer patients
- Converts uric acid to easily excretable allantoin
- Improves outcomes in tumor lysis syndrome
Side Effects
- Hypersensitivity reactions (anaphylaxis, rash, urticaria)
- Hemolysis (especially in G6PD deficient patients)
- Methemoglobinemia
- Fever
- Nausea
- Vomiting
- Headache
- Abdominal pain
- Diarrhea
- Peripheral edema
- Dyspnea
- Hypotension
Safety Measures
- Alcohol - No specific interaction, but general health advice applies; avoid excessive intake.
- Pregnancy - Use only if clearly needed, as animal studies show potential harm; weigh benefits against risks.
- Breastfeeding - Unknown if excreted in human milk; caution advised, consider discontinuing breastfeeding.
- Liver - Use with caution in patients with hepatic impairment; no specific dose adjustment guidelines.
- Kidney - Primarily used to prevent kidney injury; no specific dose adjustment for existing renal impairment.
- Lung - Monitor for respiratory symptoms, as dyspnea and bronchospasm can occur as part of hypersensitivity reactions.
Disclaimer
MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.
Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.
Our goal is to complement, not replace, the essential doctor-patient relationship.
| Shipping Cost |
|
| Shop Location | Assam, India |
No comments found for this product. Be the first to comment!